EAST RUTHERFORD, N.J., Sept. 16 Cambrex Corporation (NYSE: CBM) announced today that its Continuous-Flow Microwave-Assisted Organic Synthesis (CF-MAOS) technology has been accepted as a nominee for the 2009 Innovations Awards at CPhI, an important upcoming pharmaceutical ingredients exhibition to be held in Madrid, Spain.
Advertisement
The CF-MAOS technology represents a dual technological breakthrough, allowing both the scale-up of microwave-assisted chemistry and the handling of heterogeneous mixtures in continuous-flow. This new technology will finally bring the benefits of both technologies out of the laboratory and into production. The CaMWave(TM) KiloLAB flow reactor is capable of manufacturing in excess of 20 kilograms of product per day, and combined with larger reactors, can generate more than one hundred metric tons of product per year. This versatile technology facilitates faster, cleaner, more reliable reactions, leading to improved productivity and lower manufacturing costs.
Advertisement
About Cambrex
Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including active pharmaceutical ingredients ("API"), advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals. For more information, please visit www.cambrex.com.
The technology will be presented during the CPhI Innovation Awards: Title: Microwave Chemistry - Out of the Lab and Into Production Speaker: Dr. Jayne E. Muir Date: October 13, 2009 Location: Hall 10, Stand 10G16 Time: 11:00-11:20 a.m. Visit Cambrex at CPhI in Madrid at Feria de Madrid Hall 3, Stand 3C70 on October 13-15, 2009.
SOURCE Cambrex Corporation
